Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: Casaubon who wrote (579)	4/24/2002 3:33:12 PM
From: dalroi	Read Replies (1) \| Respond to of 1169

this is the reason Drug developers Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and Aventis SA (SBF:AVEP) said on Wednesday their experimental arthritis drug did not prove significantly more effective than a placebo. Shares of tiny Vertex were off $5.51, or 19 percent, at $23.25 in afternoon Nasdaq trading. Shares of Aventis, which has a much larger pipeline and portfolio of drugs, were up $1.02 to $70.02 on the New York Stock Exchange. In the mid-stage, or Phase II, trials reported Wednesday, Vertex and Aventis reported that rheumatoid arthritis patients on the experimental drug showed improvement in symptoms of the disorder, but the benefit was not statistically significant. Rheumatoid arthritis occurs when the body's immune system becomes overactive, causing pain and discomfort in the joints. Cambridge, Massachusetts-based Vertex and Aventis of France said they plans to "expand" clinical development of the drug,